Skip to main content

Leukodystrophy, Globoid Cell

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
PBKR03Phase 1/21 trial
Active Trials
NCT04771416Suspended24Est. Jan 2030
GEMMA Biotherapeutics
GEMMA BiotherapeuticsPA - Philadelphia
1 program
1
PBKR03Phase 1/2

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
BioTherapeutics IncPBKR03

Clinical Trials (1)

Total enrollment: 24 patients across 1 trials

Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease

Start: Feb 2022Est. completion: Jan 203024 patients
Phase 1/2Suspended

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.